BioPontis Alliance and Taconic Enter Into Scientific Development Partnership
News Dec 02, 2010
Taconic has been supplying a wide range of such models to pharmaceutical companies and academic institutions for many years. Recently, with the development of its translational mouse models for ADME and oncology portfolios, Taconic has brought together collections of translational mouse models to specifically address disease and drug discovery related questions in oncology and drug metabolism. Taconic links these models into its compound profiling platform to provide an integrated product and service offering.
Through its development fund and a unique first-in-kind business model, BioPontis Alliance seeks to bridge the gap between academic discovery science and the development and commercialization of effective therapies. The company reduces early stage development risk by selecting promising science and working with its inventors to advance it toward drug or diagnostic product pipelines. BioPontis Alliance's scientific and commercialization experts work in collaboration with leading university partners, focusing their efforts primarily on cancer, infectious disease and select neurological disorders.
"Of the thousands of biomedical innovations generated each year, only a few are successfully advanced toward drug discovery pipelines and eventually commercialized," said Todd F. Little, Taconic President and CEO. "As a company dedicated to improving drug discovery and human health, Taconic is proud to work in partnership with BioPontis Alliance, a unique organization committed to turning promising innovations into effective biomedical therapies."
Taconic will serve as BioPontis Alliance's exclusive provider of genetically modified models used in oncology applications. Taconic is also the company's preferred provider for in vivo clinical studies in the areas of oncology, neurology and infectious disease; compound profiling services; phenotyping services; and custom-generated models for use in preclinical efficacy and safety testing. To support its oncology initiatives, BioPontis also will leverage Taconic's advanced bioluminescent imaging of tumor cells, along with its genetically modified models predisposed to tumor development.
"Sophisticated, precisely defined animal models are vital to the in vivo translational research that is the foundation of BioPontis Alliance's mission," said Dr. Barbara Handelin, President of BioPontis Alliance. "Taconic's robust line of genetically modified models, advanced custom model generation services and reliable scientific services will serve as critical tools that enable us to help our partners turn promising science into successful medical products."
A new experimental system has been designed that can rapidly assess the pathogenic effects of a drug on a baby's developing brain. The system uses embryonic stem cells reprogrammed into neurons, and offers a powerful tool for probing genetic and molecular underpinnings of drug-induced neurodevelopmental disorders.READ MORE
An investigational drug for the treatment of sickle cell disease shows early promise in Phase 2a clinical trial. The orally administered drug, given to adult patients with sickle cell disease, is demonstrating tolerability and the ability to impact both red and white blood cell biomarkers of the disease.READ MORE